Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma
Cancer Medicine · 2023
DOI: 10.1002/cam4.6282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Maho Onda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Aichi Medical University Hospital, Nagakute, Japan. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal growth factor receptor (EGFR) is frequently overexpressed in oral squamous cell carcinoma (OSCC), and EGFR‐targeting therapeutics have been widely employed to treat patients with a variety of carcinomas including OSCC. Here, we aimed to investigate alternative signaling for OSCC survival under the disruption of EGFR signaling.
Methods
OSCC cell lines, namely HSC‐3 and SAS, were utilized to investigate how EGFR disruption affects cell proliferation. Gene set enrichment analysis was performed to examine how EGFR disruption affects oncogenic signaling in OSCC cells. Disruption of KDR gene was performed using CRISPR/Cas9 techniques. A VEGFR inhibitor, vatalanib was used to research the impact of VEGFR inhibition on OSCC survival.
Results
EGFR disruption significantly decreased the proliferation and oncogenic signaling including Myc and PI3K‐Akt, in OSCC cells. Chemical library screening assays revealed that VEGFR inhibitors continued to inhibit the proliferation of EGFR ‐deficient OSCC cells. In addition, CRISPR‐mediated disruption of KDR / VEGFR2 retarded OSCC cell proliferation. Furthermore, combined erlotinib–vatalanib treatment exhibited a more potent anti‐proliferative effect on OSCC cells, compared to either monotherapy. The combined therapy effectively suppressed the phosphorylation levels of Akt but not p44/42.
Conclusion
VEGFR‐mediated signaling would be an alternative signaling pathway for the survival of OSCC cells under the disruption of EGFR signaling. These results highlight the clinical application of VEGFR inhibitors in the development of multi‐molecular‐targeted therapeutics against OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Aichi Medical University Hospital, Nagakute, Japan.
- Department of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Japan.
- Department of Food and Nutritional Environment, College of Human Life and Environment, Kinjo Gakuin University, Nagoya, Japan.
ORCID-Profile: Akinobu Ota, Sivasundaram Karnan
Zitieren
APA
Onda, M., Ota, A., Ito, K., Ono, T., Karnan, S., Kato, M., Kondo, S., Furuhashi, A., Hayashi, T., Hosokawa, Y., & Kazaoka, Y. (2023). Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6282
Vancouver
Onda M, Ota A, Ito K, Ono T, Karnan S, Kato M, et al. Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.6282
BibTeX
@article{Onda2023,
author = {Onda, Maho and Ota, Akinobu and Ito, Kunihiro and Ono, Takayuki and Karnan, Sivasundaram and Kato, Mikako and Kondo, Sayuri and Furuhashi, Akifumi and Hayashi, Tomio and Hosokawa, Yoshitaka and Kazaoka, Yoshiaki},
title = {Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6282}
}
EUVIMED